1921
Volume 74, Issue 5
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

The safety of mefloquine has not been well described in military populations. This study used standard military databases for mefloquine prescriptions and hospitalizations to investigate mefloquine safety among US service members from 2002 through 2004. Mefloquine-prescribed and deployed personnel ( = 8,858) were compared with two reference groups. The reference groups comprised US service members who were not prescribed mefloquine and resided in Europe or Japan ( = 156,203) or had been otherwise deployed ( = 232,381). In comparison with active-duty US service members residing in Europe or Japan, mefloquine-prescribed service members were at statistically significant decreased hazard for any-cause hospitalization, as well as diseases of the respiratory and digestive systems, musculoskeletal system and connective tissue diseases, injuries and poisonings, ill-defined conditions, and mood disorders. These results suggest there is no association between mefloquine prescriptions and severe health effects, as measured by hospitalizations, across a wide range of outcomes.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.2006.74.744
2006-05-01
2018-12-18
Loading full text...

Full text loading...

/deliver/fulltext/14761645/74/5/0740744.html?itemId=/content/journals/10.4269/ajtmh.2006.74.744&mimeType=html&fmt=ahah

References

  1. Food and Drug Administration, Approval history, Lariam. Available online at http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#apphist. Accessed May 17, 2004.
  2. Borruat FX, Nater B, Robyn L, Genton B, 2001. Prolonged visual illusions induced by mefloquine (Lariam): a case report. J Travel Med 8 : 148–149. [Google Scholar]
  3. Even C, Friedman S, Lanouar K, 2001. Bipolar disorder after mefloquine treatment. J Psychiatry Neurosc 26 : 252–253. [Google Scholar]
  4. Fuller SJ, Naraqi S, Gilessi G, 2002. Paranoid psychosis related to mefloquine antimalarial prophylaxis. Papua New Guinea Med J 45 : 219–221. [Google Scholar]
  5. Havaldar PV, Mogale KD, 2000. Mefloquine-induced psychosis. Pediatr Infect Dis J 19 : 166–167. [Google Scholar]
  6. Schiemann R, Coulaud JP, Bouchaud O, 2000. Seizures after antimalarial medication in previously healthy persons. J Travel Med 7 : 155–156. [Google Scholar]
  7. Dietz A, Frolich L, 2002. Mefloquine-induced paranoid psychosis and subsequent major depression in a 25-year-old student. Pharmacopsychiatry 35 : 200–202. [Google Scholar]
  8. Javorsky DJ, Tremont G, Keitner GI, Parmentier AH, 2001. Cognitive and neuropsychiatric side effects of mefloquine. J Neuropsychiatry Clin Neurosci 13 : 242–243. [Google Scholar]
  9. Lysack JT, Lysack CL, Kvern BL, 1998. A severe adverse reaction to mefloquine and chloroquine prophylaxis. Aust Fam Physician 27 : 1119–1120. [Google Scholar]
  10. Sowunmi A, Adio RA, Oduola AM, Ogundahunsi OA, Salako LA, 1995. Acute psychosis after mefloquine. report of six cases. Trop Geogr Med 47 : 179–180. [Google Scholar]
  11. Sowunmi A, 1994. Acute psychosis after mefloquine: a case report. East Afr Med J 71 : 818–819. [Google Scholar]
  12. Hennequin C, Bouree P, Bazin N, Bisaro F, Feline A, 1994. Severe psychiatric side effects observed during prophylaxis and treatment with mefloquine. Arch Int Med 154 : 2360–2362. [Google Scholar]
  13. Caillon E, Schmitt L, Moron P, 1992. Acute depressive symptoms after mefloquine treatment. Am J Psychiatry 149 : 712. [Google Scholar]
  14. Wienke T, Trautmann M, Held T, Weber G, Eichenlaub D, Fleischer K, Kern W, Pohle HD, 1991. Neuropsychiatric side effects after the use of mefloquine. Am J Trop Med Hyg 45 : 86–91. [Google Scholar]
  15. Patchen LC, Campbell CC, Williams SB, 1989. Neurologic reactions after a therapeutic dose of mefloquine. N Engl J Med 321 : 1415–1416. [Google Scholar]
  16. Bjorkman A. Acute psychosis following mefloquine prophylaxis [letter]. Lancet 2: 865. [Google Scholar]
  17. Watt-Smith S, Mehta K, Scully C, 2001. Mefloquine-induced trigeminal sensory neuropathy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 92 : 163–165. [Google Scholar]
  18. Jimeniz-Huete A, Gil-Nagel A, Franch O, 2002. Multifocal myoclonus associated with mefloquine prophylaxis. Clin Neuropharmacol 25 : 243. [Google Scholar]
  19. Petersen E, Ronne T, Ronn A, Bygbjerg I, Olesen Larsen S, 2000. Reported side effects to chloroquine, chloroquine plus proguanil, and mefloquine as chemoprophylaxis against malaria in Danish travelers. J Travel Med 7 : 79–84. [Google Scholar]
  20. Potasman I, Beny A, Seligmann H, 2000. Neuropsychiatric problems in 2,500 long-term young travelers to the tropics. J Travel Med 7 : 5–9. [Google Scholar]
  21. Schwartz E, Potasman I, Rotenberg MSA, Sadetzki S, 2001. Serious adverse events of mefloquine in relation to blood level and gender. Am J Trop Med Hyg 65 : 189–192. [Google Scholar]
  22. Meier CR, Wilcock K, Jick SS, 2004. The risk of severe depression, psychosis, or panic attacks with prophylactic antimalarials. Drug Saf 27 : 203–213. [Google Scholar]
  23. Barrett PJ, Emmins PD, Clarke PD, Bradley DJ, 1996. Comparison of adverse events associated with use of mefloquine and combination of chloroquine and proguanil as antimalarial prophylaxis: postal and telephone survey of travellers. BMJ 313 : 525–528. [Google Scholar]
  24. Overbosch D, Schilthuis H, Bienzle U, Behrens RH, Kain KC, Clarke PD, Toovey S, Knobloch J, Nothdurft HD, Shaw D, Roskell NS, Chulay JD, Malarone International Study Team, 2001. Atovaquone-proguanil versus mefloquine for malaria prophylaxis in nonimmune travelers: results from a randomized, double-blind study. Clin Infect Dis 33 : 1015–1021. [Google Scholar]
  25. van Riemsdijk MM, Sturkenboom MC, Ditters JM, Ligthelm R, Overbosch D, Stricker BH, 2002. Atovaquone plus chloro-quanide versus mefloquine for malaria prophylaxis: a focus on neuropsychiatric adverse events. Clin Pharmacol Ther 27 : 294–301. [Google Scholar]
  26. Schlagenhauf P, Tschopp A, Johnson R, Nothdurft HD, Beck B, Schwartz E, Herold M, Krebs B, Veit O, Allwinn R, Steffen R, 2003. Tolerability of malaria chemoprophylaxis in non-immune travellers to sub-Saharan Africa: multicentre, randomised, double blind, four arm study. BMJ 327 : 1078. [Google Scholar]
  27. Ohrt C, Richie TL, Widjaja H, Shanks GD, Fitriadi J, Fryauff DJ, Handschin J, Tang D, Sandjaja B, Tjitra E, Hadiarso L, Watt G, Wignall FS, 1997. Mefloquine compared with doxycycline for the prophylaxis of malaria in Indonesian Soldiers: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 126 : 963–972. [Google Scholar]
  28. Boudreau E, Schuster B, Sanchez J, Novakowski W, Johnson R, Redmond D, Hanson R, Dausel L, 1993. Tolerability of prophylactic Lariam regimens. Trop Med Parasitol 44 : 257–265. [Google Scholar]
  29. van Riemsdijk MM, Ditters JM, Sturkenboom MC, Tulen JH, Ligthelm RJ, Overbosch D, Stricker BH, 2002. Neuropsychiatric events during prophylactic use of mefloquine before travelling. Eur J Clin Pharmacol 58 : 441–445. [Google Scholar]
  30. Jaspers CA, Hopperus Buma AP, van Thiel PP, van Hulst RA, Kager PA, 1996. Tolerance of mefloquine chemoprophylaxis in Dutch military personnel. Am J Trop Med Hyg 55 : 230–234. [Google Scholar]
  31. Kitchener SJ, Nasveld PE, Gregory RM, Edstein MD, 2005. Mefloquine and doxycycline malaria prophylaxis in Australian soldiers in East Timor. Med J Aust 182 : 168–171. [Google Scholar]
  32. Wallace MR, Sharp T, Smoak B, Iriye C, Rozmajzl P, Thornton SA, Batchelor R, Magill AJ, Lobel HO, Longer CF, Burans JP, 1996. Malaria among United States troops in Somalia. Am J Med 100 : 49–55. [Google Scholar]
  33. Arthur JD, Echeverria P, Shanks GD, Karwacki J, Bodhidatta L, Brown JE, 1990. A comparative study of gastrointestinal infections in United Sates soldiers receiving doxycycline or mefloquine for malaria prophylaxis. Am J Trop Med Hyg 43 : 608–613. [Google Scholar]
  34. Croft AM, Clayton TC, World MJ, 1997. Side effects of mefloquine prophylaxis for malaria: an independent randomized controlled trial. Trans R Soc Trop Med Hyg 91 : 199–203. [Google Scholar]
  35. Office of the Secretary of Defense, Pharmacy data transaction service. Available online at http://www.tricare.osd.mil/pharmacy/PDTS.cfm. Accessed March 30, 2005.
  36. U.S. Department of Health and Human Services, 1980. International Classification of Diseases 9th Revision Clinical Modification. Washington, DC: US Government Printing Office.
  37. Engel CC, Ursano R, Magruder C, Tartaglione R, Jing Z, Labbate LA, Debakey S, 1999. Psychological conditions diagnosed among veterans seeking Department of Defense care for Gulf War-related health concerns. J Occup Environ Med 51 : 384–392. [Google Scholar]
  38. Olmsted D, Military drops toxic-drug diagnosis. Available online at http://www.upi.com/view.cfm?StoryID=20050131-112824-7183r. Accessed March 16, 2005.
  39. SAS Institute, 2004. SAS/STAT® 9.1 Users Guide. Cary, NC: SAS Institute.
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.2006.74.744
Loading
/content/journals/10.4269/ajtmh.2006.74.744
Loading

Data & Media loading...

  • Received : 08 Sep 2005
  • Accepted : 27 Dec 2005

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error